KRAS and neoplasm: Hence, it is actually unknown if the here analyzed ADAM17 mutations are actively driving tumorigenesis (‘driver mutation’) or if another mutation, e.g., within the oncogene KRAS gene [47] is primarily involved in tumor formation and variants within ADAM17 are found as a so-called ‘passenger mutations’ [48,49].